000186453 001__ 186453
000186453 005__ 20240229145746.0
000186453 0247_ $$2doi$$a10.1001/jamanetworkopen.2022.48447
000186453 0247_ $$2pmid$$apmid:36547977
000186453 0247_ $$2altmetric$$aaltmetric:140449127
000186453 037__ $$aDKFZ-2022-03174
000186453 041__ $$aEnglish
000186453 082__ $$a610
000186453 1001_ $$0P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9$$aChen, Xuechen$$b0$$eFirst author$$udkfz
000186453 245__ $$aAssessment of Body Mass Index, Polygenic Risk Score, and Development of Colorectal Cancer.
000186453 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2022
000186453 3367_ $$2DRIVER$$aarticle
000186453 3367_ $$2DataCite$$aOutput Types/Journal article
000186453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1672317381_10725
000186453 3367_ $$2BibTeX$$aARTICLE
000186453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186453 3367_ $$00$$2EndNote$$aJournal Article
000186453 500__ $$a#EA:C070#LA:C070#LA:C120#
000186453 520__ $$aExcess weight, the prevalence of which is high and increasing in many countries, is linked to multiple adverse health outcomes, including increased colorectal cancer (CRC) risk. Better communication of health risks associated with excess weight might support efforts of prevention.To evaluate the individual and joint associations of body mass index (BMI) and polygenic risk with CRC, to assess potential interactions among them, and to quantify by how much increased polygenic risk for CRC can be offset by having a BMI within reference range.This population-based case-control study was conducted in the Rhine-Neckar region of southwest Germany, with recruitment from 2003 to 2017. Participants with both risk factor and genetic information were included for analysis. Data analysis was conducted from December 8, 2021, to February 17, 2022.BMI was calculated as self-reported weight in kilograms approximately 10 years before diagnosis or interview and current height in meters squared. A polygenic risk score (PRS) was built based on 140 CRC-related risk loci.Individual and joint associations of BMI and PRS with CRC were estimated using multiple logistic regression. Associations of excess weight with CRC were quantified by adjusted odds ratios (aORs) and genetic risk equivalents (GREs), the equivalent outcomes conveyed by defined differences in PRS percentiles.Among 9169 participants (median [IQR] age, 69 [62-76] years; 5589 [61.0%] male participants) included, 5053 had CRC and 4116 did not. BMI of 30 or greater was associated with higher odds of having CRC compared with BMI less than 25 (aOR, 1.71; 95% CI, 1.49-1.97), independent of PRS levels (P for interaction = .45). Participants with BMI of 30 or greater and a PRS in the highest tertile had higher odds of CRC compared with participants with BMI less than 25 and a PRS in the lowest tertile (aOR, 3.82; 95% CI, 3.03-4.82). The estimated association of BMI greater than 30 with CRC risk was equivalent to that of having a 41 (95% CI, 29-53)-percentile higher PRS. BMI of 30 or greater was particularly associated with stage IV CRC (aOR, 2.21; 95% CI, 1.71-2.84).These findings suggest that excess weight was associated with CRC regardless of PRS levels. The association of having a BMI within reference range may be similar to that of having a substantially lower polygenic risk for CRC.
000186453 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186453 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186453 650_2 $$2MeSH$$aHumans
000186453 650_2 $$2MeSH$$aMale
000186453 650_2 $$2MeSH$$aAged
000186453 650_2 $$2MeSH$$aFemale
000186453 650_2 $$2MeSH$$aBody Mass Index
000186453 650_2 $$2MeSH$$aCase-Control Studies
000186453 650_2 $$2MeSH$$aRisk Factors
000186453 650_2 $$2MeSH$$aWeight Gain
000186453 650_2 $$2MeSH$$aColorectal Neoplasms: epidemiology
000186453 650_2 $$2MeSH$$aColorectal Neoplasms: genetics
000186453 7001_ $$0P:(DE-He78)40c45b31a82f8311dd3a7363bd758720$$aLi, Hengjing$$b1$$udkfz
000186453 7001_ $$0P:(DE-He78)6c325c717056d7ccd38066629f7dff6b$$aMandic, Marko$$b2$$udkfz
000186453 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b3$$udkfz
000186453 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000186453 773__ $$0PERI:(DE-600)2931249-8$$a10.1001/jamanetworkopen.2022.48447$$gVol. 5, no. 12, p. e2248447 -$$n12$$pe2248447 -$$tJAMA network open$$v5$$x2574-3805$$y2022
000186453 909CO $$ooai:inrepo02.dkfz.de:186453$$pVDB
000186453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c392ec8a090dcfbe801f135a6212caf9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)40c45b31a82f8311dd3a7363bd758720$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000186453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c325c717056d7ccd38066629f7dff6b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000186453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000186453 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000186453 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186453 9141_ $$y2022
000186453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA NETW OPEN : 2021$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-10-18T13:36:16Z
000186453 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-10-18T13:36:16Z
000186453 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-10-18T13:36:16Z
000186453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJAMA NETW OPEN : 2021$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000186453 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000186453 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000186453 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000186453 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000186453 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000186453 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000186453 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000186453 980__ $$ajournal
000186453 980__ $$aVDB
000186453 980__ $$aI:(DE-He78)C070-20160331
000186453 980__ $$aI:(DE-He78)C120-20160331
000186453 980__ $$aI:(DE-He78)HD01-20160331
000186453 980__ $$aUNRESTRICTED